Salesforce’s (CRM) Agentforce Life Sciences platform continues to gain momentum across the healthcare industry. Recently, Novartis (NVS) expanded its partnership with Salesforce to unify and personalize how it engages with healthcare professionals (HCPs) and patients globally over the next five years.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Under the new agreement, Novartis will deploy Agentforce 360 for Life Sciences to connect its marketing, sales, patient services, and medical teams, creating a more seamless and coordinated customer experience.
The initiative aims to streamline operations, strengthen insights, and ensure compliance, building on the suite of Salesforce health solutions the company already uses.
Frank Defesche, General Manager of Life Sciences at Salesforce, said the expanded partnership “underscores our commitment to transforming how the life sciences industry engages with marketing, sales, and medical stakeholders,” adding that the goal is to help patients receive the right therapies when they need them.
Pharma Giants Continue Turning to Salesforce
Importantly, AstraZeneca (AZN) also adopted the platform earlier in December, reflecting the growing influence of AI engagement tools in life sciences. Other major pharmaceutical companies, including Pfizer (PFE), Sanofi (SNY), Eli Lilly (LLY), and Amgen (AMGN), have also embraced Salesforce’s Agentforce Life Sciences offerings.
These companies rely on tools such as Salesforce’s core CRM, Sales Cloud, or the industry-specific Life Sciences Cloud, to manage customer relationships, standardize data, and improve operational efficiency across global markets.
Is CRM a Buy, Sell, or Hold?
Turning to Wall Street, CRM stock has a Moderate Buy consensus rating based on 31 Buys, 10 Holds, and one Sell assigned in the last three months. At $327.13, the average Salesforce stock price target implies a 25.7% upside potential.
